HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nonprofit Pharmaceutical Companies

483.155

-13.603-2.74%

Number of Gainers:7

Number of Losers:23

Number of Flat:3

PE:- -

High:496.758

Open:496.758

Low:480.328

Close:496.758

Volume:115.32M

Turnover:2.61B

Market Cap:306.93B

Float Cap:273.30B

Loading ...

Acotec Scientific FY26 H1 Swings to Net Loss of RMB 80.83 Million; Revenue Falls 5.6% to RMB 331.58 Million

Acotec Scientific - Hy Revenue RMB 331.6 Mln

THOMSON REUTERS

Acotec Scientific Holdings Limited - Board Does Recommend Payment of Interim Dividend

THOMSON REUTERS

Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation

China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume

Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses

OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China

Ocumension Completes First Patient Enrollment in Phase III China Trial of Dry Eye Drug OT-202

China's So-Young Q2 Revenue Rises, Net Loss Narrows

China's Rainmed Medical H1 Revenue Rises, Net Loss Narrows

Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales

Lee's Pharm Reports 41.4% Profit Surge in H1 Results

China's HeartCare Medical H1 Revenue Surges on Stroke Segment Growth

Shanghai HeartCare Medical Technology - Board Did not Declare the Payment of an Interim Dividend

THOMSON REUTERS

Shanghai HeartCare H1 FY26 Profit Climbs 18.5% to RMB 60.37 Million; Revenue Rises 56.9% to RMB 291.03 Million

Shanghai HeartCare Medical Technology H1 Revenue RMB 291 Million

THOMSON REUTERS

Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate

AH Share Premium Report: August 31 Market Close

Ascletis Pharma Starts Phase III Trial of Weight-Loss Drug; Shares Plummet 5%

MT Newswires Live

CanSino Leads HK-Listed Vaccine Makers Lower as BioNTech Halts mRNA Trial

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrcrest.com/stock/BK1574/news?page=12"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"Nonprofit Pharmaceutical Companies","latestPrice":483.15506,"timestamp":1789114133774,"preClose":496.75812,"halted":0,"volume":115323363,"delay":0,"changeRate":-0.027384,"floatShares":0,"shares":0,"eps":0,"marketStatus":"Closed","change":-13.603058,"latestTime":"09-11 16:00:00","open":496.75812,"high":496.75812,"low":480.32812,"amount":2611810568,"amplitude":0.033074,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1789349400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789090200000,1789099200000],[1789102800000,1789113600000]],"pbRate":3.703217,"peRate":164.740195,"turnoverRate":0.004215,"increases":6,"decrements":25,"flats":1,"marketCap":306930068880,"floatMarketCap":273297591592},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":496.75812,"amplitude":0.033074,"preClose":496.75812,"low":480.32812,"pbRate":"3.703217","latestPrice":483.15506,"volume":115323363,"delay":0,"open":496.75812,"prevYearClose":556.26263,"prevWeekClose":532.025,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":532.025,"twentyDayClose":518.327,"sixtyDayClose":434.471,"secType":"PLATE","market":"HK","turnoverRate":0.004215,"peRate":164.740195,"marketCap":306930068880,"floatMarketCap":273297591592,"timestamp":1789114133774,"nameCN":"Nonprofit Pharmaceutical Companies"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":7,"down":23,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:12,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2663307706","title":"Acotec Scientific FY26 H1 Swings to Net Loss of RMB 80.83 Million; Revenue Falls 5.6% to RMB 331.58 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663307706","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663307706?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:21","pubTimestamp":1788175287,"startTime":"0","endTime":"0","summary":"Acotec Scientific FY26 H1 swings to net loss of RMB 80.83 million; revenue falls 5.6% to RMB 331.58 millionAcotec Scientific posted an IFRS net loss of RMB 80.83 million, swinging from profit; basic E","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL8vjVj7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0138981039.USD","LU0823417737.USD","LU2324357040.USD","LU1718418525.SGD","LU0251132253.USD","LU1791710400.SGD","SGXZ57979304.SGD","LU2362541513.USD","BK1587","LU0345769631.USD","LU2506952170.USD","LU0353189763.USD","BSX","LU2242649171.HKD","LU0345769128.USD","LU2362541273.HKD","IE00BFTCPJ56.SGD","LU0823416689.USD","LU1989772923.USD","SG9999001176.USD","LU0823417653.USD","IE00BJJMRZ35.SGD","LU0432979614.USD","LU1061106388.HKD","LU1989772840.SGD","LU1989771016.USD","LU2265009873.SGD","LU1989764664.SGD","BK1100","LU0882574055.USD","BK1574","LU1023059063.AUD","SG9999001176.SGD","LU2506952097.USD","LU0225283273.USD","06669","LU0353189680.USD","LU0950375773.USD","LU2357305700.SGD","LU0122379950.USD","LU2244417387.USD","LU2491049909.HKD","IE00BJT1NW94.SGD","IE0002141913.USD","LU1720051108.HKD","IE00B4R5TH58.HKD","LU2491050154.USD","LU1057294990.SGD","LU1366192091.USD","LU2506951875.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077780","title":"Acotec Scientific - Hy Revenue RMB 331.6 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077780","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077780?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:20","pubTimestamp":1788175256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0BK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06669","BK1574","BK1100","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077039","title":"Acotec Scientific Holdings Limited - Board Does Recommend Payment of Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077039","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077039?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:20","pubTimestamp":1788175256,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44S0BK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1587","BK1100","BK1574","06669"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077197","title":"Zylox-Tonbridge Files HKEX Next-Day Disclosure Return on Share Repurchase for Cancellation","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077197","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077197?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:14","pubTimestamp":1788174854,"startTime":"0","endTime":"0","summary":"Zylox-Tonbridge files HKEX next-day disclosure return on share repurchase for cancellationZylox-Tonbridge bought back 53,000 H shares on Aug. 31, holding them as treasury shares; no shares were cancel","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL5gftGB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02190","BK1100","BK1587","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663077162","title":"China's Angelalign H1 Revenue Rises on Higher Clear Aligner Case Volume","url":"https://stock-news.laohu8.com/highlight/detail?id=2663077162","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663077162?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:13","pubTimestamp":1788174790,"startTime":"0","endTime":"0","summary":"China's Angelalign H1 revenue rises on higher clear aligner case volumeOverviewChina clear aligner maker's H1 2026 revenue rose 42.9% yr/yrAdjusted net profit for H1 2026 grew 79.5% yr/yrCompany attri","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0DA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1593","06622","01477","BK1574","BK1191","BK1587","06609","06699","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663686077","title":"Israel's BioLineRx Q2 Net Loss Widens on Higher R&D Expenses","url":"https://stock-news.laohu8.com/highlight/detail?id=2663686077","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663686077?lang=en_us&edition=fundamental","pubTime":"2026-08-31 19:09","pubTimestamp":1788174543,"startTime":"0","endTime":"0","summary":"Israel's BioLineRx Q2 net loss widens on higher R&DexpensesOverviewIsrael biopharma's Q2 revenue was flat yr/yr at $0.3 mlnNet loss widened to $4.3 mln from $3.9 mln on higher R&D and admin expensesCo","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0D4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BLRX","BK1191","01477","01228","BK1574","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131581918","title":"OCUMENSION-B's Dry Eye Candidate OT-202 Commences Late-Stage Dosing in China","url":"https://stock-news.laohu8.com/highlight/detail?id=1131581918","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131581918?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:28","pubTimestamp":1788172096,"startTime":"0","endTime":"0","summary":"OCUMENSION-B (01477) has announced that the first patient has been enrolled in the Chinese Phase III clinical trial for OT-202, its investigational therapy for dry eye disease (DED). This milestone...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IBBQ","BK1191","PSYK","BK1574","BMED","IBBJ","01477","MDTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663074131","title":"Ocumension Completes First Patient Enrollment in Phase III China Trial of Dry Eye Drug OT-202","url":"https://stock-news.laohu8.com/highlight/detail?id=2663074131","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663074131?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:25","pubTimestamp":1788171922,"startTime":"0","endTime":"0","summary":"Ocumension completes first patient enrollment in Phase III China trial of dry eye drug OT-202Ocumension Therapeutics completed first patient enrollment in a China Phase III trial of OT-202 for moderat","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL64Bjf6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663878074","title":"China's So-Young Q2 Revenue Rises, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2663878074","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663878074?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:11","pubTimestamp":1788171110,"startTime":"0","endTime":"0","summary":"China's So-Young Q2 revenue rises, net loss narrowsOverviewChina aesthetic treatment platform's Q2 revenue rose 33% yr/yr, driven by branded center expansionNet loss for Q2 narrowed yr/yr, reflecting ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0BC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4563","BK1574","06609","BK1587","SY","BK4077","BK4503","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071777","title":"China's Rainmed Medical H1 Revenue Rises, Net Loss Narrows","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071777","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663071777?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:08","pubTimestamp":1788170928,"startTime":"0","endTime":"0","summary":"China's Rainmed Medical H1 revenue rises, net loss narrowsOverviewChina medical device maker's H1 revenue rose 41% yr/yr, driven by caFFR system salesNet loss attributable to shareholders narrowed to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0BA:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","06609","BK1191","01228","BK1587","BK1100","01477","02297"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663437071","title":"Hong Kong's Lee's Pharmaceutical H1 Profit Jumps on Higher-Margin Product Sales","url":"https://stock-news.laohu8.com/highlight/detail?id=2663437071","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663437071?lang=en_us&edition=fundamental","pubTime":"2026-08-31 18:00","pubTimestamp":1788170409,"startTime":"0","endTime":"0","summary":"Hong Kong's Lee's Pharmaceutical H1 profit jumps on higher-margin product salesOverviewHong Kong pharma maker's interim revenue grew 14.6% yr/yr for six months ended June 2026Net income attributable t","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S0AP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1606","BK1583","BK1515","06622","01477","BK1587","00570","BK1191","BK1574","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1121505356","title":"Lee's Pharm Reports 41.4% Profit Surge in H1 Results","url":"https://stock-news.laohu8.com/highlight/detail?id=1121505356","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1121505356?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:54","pubTimestamp":1788170056,"startTime":"0","endTime":"0","summary":"LEE'S PHARM (00950) has announced its interim results for 2026, posting a revenue of approximately HK$797 million, marking a year-on-year increase of 14.6%.The company recorded a profit attributable...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1587","BK1191","BK1574","BK1583","00950"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663928076","title":"China's HeartCare Medical H1 Revenue Surges on Stroke Segment Growth","url":"https://stock-news.laohu8.com/highlight/detail?id=2663928076","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663928076?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:14","pubTimestamp":1788167685,"startTime":"0","endTime":"0","summary":"China's HeartCare Medical H1 revenue surges on stroke segment growthOverviewChina medical device maker's H1 revenue rose 56.9% yr/yr to RMB291 mlnNet profit attributable to shareholders grew 18.5% yr/","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S09G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0188","BK0097","BK1191","01477","600085","BK0028","BK1587","06609","BK0239","BK0183","BK0012","BK1606","06622","BK1100","01666","BK1574","BK0196","LU1688375341.USD","BK1515","BK0113","BK1583","BK0086"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663763580","title":"Shanghai HeartCare Medical Technology - Board Did not Declare the Payment of an Interim Dividend","url":"https://stock-news.laohu8.com/highlight/detail?id=2663763580","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663763580?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:02","pubTimestamp":1788166975,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44R07R:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["06609","BK1587","BK1100","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076351","title":"Shanghai HeartCare H1 FY26 Profit Climbs 18.5% to RMB 60.37 Million; Revenue Rises 56.9% to RMB 291.03 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076351","media":"Reuters","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076351?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:02","pubTimestamp":1788166937,"startTime":"0","endTime":"0","summary":"Shanghai HeartCare H1 FY26 profit climbs 18.5% to RMB 60.37 million; revenue rises 56.9% to RMB 291.03 millionShanghai HeartCare posted revenue of RMB 291.03 million, up 56.9% year over year; profit a","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nNDL636RtR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1587","BK1100","BK1574","06609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663076331","title":"Shanghai HeartCare Medical Technology H1 Revenue RMB 291 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2663076331","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663076331?lang=en_us&edition=fundamental","pubTime":"2026-08-31 17:02","pubTimestamp":1788166936,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nPLXBXPQPP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1100","BK1587","BK1574","06609"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115184678","title":"Guangdong Hybribio Biotech's Subsidiary Secures In Vitro Diagnostic Device Registration Certificate","url":"https://stock-news.laohu8.com/highlight/detail?id=1115184678","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115184678?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:40","pubTimestamp":1788165635,"startTime":"0","endTime":"0","summary":"Guangdong Hybribio Biotech Co., Ltd. (300639.SZ) announced that its wholly-owned subsidiary, Chaozhou Kaipu Bio-Chemistry Co., Ltd. (referred to as \"Kaipu Chemistry\"), has recently obtained the...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["159883","RSPH","BK1583","BK0239","AGNG","HART","IEIH","BK0132","BK1574","BK1100","GDOC","300639","LNGR","BK0042","MEDX","BK0046","MDEV","PTH","09996","LGHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1102447356","title":"AH Share Premium Report: August 31 Market Close","url":"https://stock-news.laohu8.com/highlight/detail?id=1102447356","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1102447356?lang=en_us&edition=fundamental","pubTime":"2026-08-31 16:21","pubTimestamp":1788164495,"startTime":"0","endTime":"0","summary":"As of the close on August 31, data shows NE ELECTRIC (00042), ZHEJIANG SHIBAO (01057), and HOLLY FUTURES (03678) hold the top three positions in the A-H share premium ranking, with premium rates of...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1242518857.USD","LU1119993845.HKD","LU2125910500.SGD","03200","82846","LU1152091754.HKD","LU1152091168.USD","SG9999011746.SGD","LU0868486357.SGD","LU1328277881.USD","IE00BYV24P56.USD","IE00BZ08YS42.EUR","IE0008369823.USD","BK1149","IE00BVYPNP33.GBP","BK1191","BK1560","LU0431992006.USD","BK1594","IE00B5MMRT66.SGD","LU0214875030.USD","BK1554","01033","BK1557","LU0210526637.USD","LU0502904849.HKD","LU0823426308.USD","BK1161","LU0254981946.USD","LU1242518931.SGD","LU1366334651.USD","LU1720050803.USD","LU2279701549.SGD","LU0348766576.USD","02475","BK1116","LU1993786604.SGD","01057","LU0359201612.USD","LU0048580855.USD","LU1244550221.USD","00187","BK1205","BK1202","LU0708995583.HKD","LU0287142896.SGD","BK1105","LU0173614495.USD","06185","LU0463099449.HKD","SG9999006597.SGD","LU0128522157.USD","03678","BK1576","01812","LU1675838814.USD","LU1770034418.SGD","LU2045819591.USD","LU0488056044.USD","LU2039709279.SGD","SG9999002463.SGD","03750","LU0348805143.USD","LU0244354667.USD","LU0417516902.SGD","BK1526","BK1607","LU0051755006.USD","LU0531970944.HKD","LU0589944569.HKD","LU0348827113.USD","HK0001040168.HKD","BK1141","01349","LU0231483743.USD","03986","HK0000352382.USD","LU1282649810.SGD","02359","LU1115378108.SGD","BK1522","LU0149534421.HKD","LU1303224171.USD","LU0164880469.USD","BK1515","LU0348816934.USD","LU0501845795.SGD","BK1574","LU1255011170.USD","LU0880133367.SGD","SG9999004220.SGD","00981","07233","BK1610","LU0229945570.USD","LU0348814723.USD","LU0791591158.USD","LU1880383440.USD","SG9999001093.SGD","LU1794554557.SGD","LU1807302812.USD","LU1960683339.HKD","03328","BK1505","LU1688375341.USD","03296","00553","LU2226246903.HKD","00753","BK1514","LU1008478684.HKD","BK1521","09981","83130","BK1223","IE00BGHQDM52.EUR","LU0607220059.USD","LU0640798160.USD","LU2476274720.SGD","LU0516423174.USD","LU0543330566.HKD","BK1249","LU1023057109.AUD","LU1481107354.HKD","LU0588546209.SGD","LU0648948544.HKD","03308","IE00BPRC5H50.USD","BK1171","BK1183","01108","LU0370786039.SGD","00991","LU1046422090.SGD","LU0149721374.USD","BK1231","IE00B031J352.USD","LU0314109678.HKD","LU2294711473.HKD","IE00B543WZ88.USD","LU1244550494.USD","BK1125","LU2048586759.USD","00568","IE00BF5LJ272.USD","06869","BK1214","LU1282649141.HKD","LU0320764599.SGD","IE0034224299.USD","LU0417516738.SGD","LU0877626530.USD","03188","LU2394011477.USD","LU1282648689.USD","BK1564","LU0918141887.USD","01513","IE00B3M56506.USD","SG9999001226.SGD","LU0572944931.SGD","LU0979878070.USD","LU0326950275.SGD","LU0228367735.SGD","LU0890818403.SGD","BK1533","LU0320764755.SGD","LU1226287529.USD","BK1562","LU2476274308.USD","LU0359202008.SGD","LU0516422440.USD","EWH","LU0561508036.HKD","LU0634319403.HKD","SG9999014674.SGD","00300","LU2399975544.HKD","LU1224709979.USD","LU0516422366.SGD","LU0516422952.EUR","LU1719994722.HKD","LU0823426480.USD","BK1123","LU1251922891.USD","BK1561","LU0163747925.USD","LU1282649067.USD","IE00BMCWC346.EUR","IE0008368742.USD","LU0737861699.HKD","LU0072913022.USD","LU0205439572.USD","IE00B0169L03.USD","02846","159982","06690","BK1530","LU0315179316.USD","LU0359201885.HKD","LU1188198961.HKD","LU1880383366.USD","LU1105468828.SGD","LU0384037296.USD","LU0348788117.USD","LU0797268264.HKD","03968","02727","IE00BZ08YT58.USD","03268","02338","BK1237","83188","LU1813983027.USD","LU2242644610.SGD","LU0052750758.USD","LU0348767384.USD","BK1523","LU0516423091.SGD","LU0067412154.USD","LU0455707207.USD","IE00B29SXG58.USD","BK1147","LU2778985437.USD","IE00BVYPNQ40.USD","BK1163","BK1551","IE0031814852.USD","LU1655091616.SGD","LU0456846285.SGD","BK1507","03143","LU0672654166.SGD","LU1244550577.SGD","LU1831875114.USD","BK1583","00042","LU0117841782.USD","LU0449509016.USD","BK1193","02827","LU0456827905.SGD","LU0469268626.HKD","LU0593848301.USD","02691","LU0029875118.USD","IE00B031HY20.USD","BK1546","LU0327786744.USD","BK1506","LU0348825331.USD","LU0791590937.USD","HK0000352291.HKD","LU1961090484.USD","01877","HK0001040143.USD","LU0106959298.USD","LU0540923850.HKD","399300","LU1211504680.USD","BK1122","BK1614","IE00BZ08YR35.GBP","02218","03130","LU0543330483.HKD","LU0307460666.USD","LU0862451753.SGD","00317","LU0918141705.HKD","LU1366334578.USD","BK1170","LU1808992512.USD","BK1144","SG9999002828.SGD","LU0348735423.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663302408","title":"Ascletis Pharma Starts Phase III Trial of Weight-Loss Drug; Shares Plummet 5%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663302408","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663302408?lang=en_us&edition=fundamental","pubTime":"2026-08-31 13:22","pubTimestamp":1788153761,"startTime":"0","endTime":"0","summary":"Ascletis Pharma  said the first participant has been dosed in a global Phase III clinical program for ASC30, an oral drug being developed for long-term weight management and diabetes.The program comprises two late-stage trials involving about 4,600 participants across the U.S., Europe and Canada to assess the drug's effectiveness, safety and tolerability, according to a Sunday Hong Kong bourse filing.Shares of the company plunged over 5% in Monday's trade.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1515","BK1574","01672"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663446024","title":"CanSino Leads HK-Listed Vaccine Makers Lower as BioNTech Halts mRNA Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2663446024","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663446024?lang=en_us&edition=fundamental","pubTime":"2026-08-31 13:10","pubTimestamp":1788153044,"startTime":"0","endTime":"0","summary":"BUZZ-CanSino leads HK-listed vaccine makers lower as BioNTech halts mRNA trial** CanSino Biologics Hong Kong stock6185.HKleads slide in HK-listed shares of Chinese vaccine makers after news that BioNT","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL1N44S04S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4551","BK4585","06185","BK1574","BNTX","BK4568","BK4139","BK1515","BK4535","688185","BK1191","BK1161","BK4548","BK4588"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":13,"pageCount":12,"totalSize":250,"code":"91000000","status":"200"}]}}